Educational information, not medical advice — ask your doctor or midwife.
Sambong (Blumea balsamifera) is a tall aromatic shrub found throughout the Philippines, Southeast Asia, and parts of East Asia. It holds a notable distinction as one of only a handful of plants officially approved by the Philippine Department of Health and included in the national formulary as a recognized herbal medicine. The plant's leaves are the primary medicinal part, used both as teas and standardized tablet preparations.
Sambong's key active compound, l-borneol (Blumea camphor), is thought to interfere with calcium oxalate crystal formation and aggregation — the building blocks of the most common type of kidney stones. It also appears to have a mild diuretic action, potentially increasing urine output and helping flush the urinary tract. Additional flavonoid content is believed to contribute anti-inflammatory and antimicrobial effects that may support urinary health.
The most traditional form is a tea brewed from dried sambong leaves, which is still widely used in rural Philippines. Standardized tablet preparations (most notably Rowatinex-adjacent products and the Philippine DOH-approved Blumea tablet) offer consistent dosing for kidney stone management. Capsules and liquid extracts are also available through herbal supplement retailers.
Sambong has been used in Philippine folk medicine for generations to treat kidney and bladder complaints, fever, and respiratory conditions. Its integration into the Philippine national health system — through formal government review and DOH approval — makes it one of the rare traditional herbal remedies to bridge folk practice and government-endorsed clinical use. It is also used in Vietnamese and Indonesian traditional medicine for similar purposes.
Evidence grades and traditional-use labels are explained in our methodology. Nothing here is medical advice.
Reviewed by the HealisticMD editorial team How we grade evidence →
What it is typically used for, usual dose, cautions, and the study behind it where real trial data exists.
One email with the summary. We'll also send a short weekly evidence update — unsubscribe any time.